Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 alpha - PubMed (original) (raw)

Affiliations

PMID: 8299739

Comparative Study

Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 alpha

S Cooper et al. Exp Hematol. 1994 Feb.

Abstract

Macrophage inflammatory protein (MIP)-1 alpha has myelosuppressive/myeloprotective effects in vivo in mice. We recently reported that > 99.7% of recombinant murine (rm) MIP-1 alpha polymerizes rapidly at relatively high concentrations in physiological salt solution, and it is the monomeric form of MIP-1 alpha that is active in vitro as a myelosuppressive factor. Polymerized MIP-1 alpha is inactive in this effect and does not block the myelosuppressive action of monomeric MIP-1 alpha. MIP-1 alpha could be maintained in monomeric form in physiological saline if diluted to low concentrations. This led us to reevaluate the actual amounts of MIP-1 alpha necessary for myelosuppression in vivo. C3H/HeJ mice were injected intravenously (i.v.) with monomeric rmMIP-1 alpha or control diluent and effects were evaluated on progenitor cells--multipotent colony-forming units (CFU-GEMM), burst-forming units-erythroid (BFU-E), and colony-forming units-granulocyte/macrophage (CFU-GM)--as described in previous studies in which MIP-1 alpha concentrations were used that we now know to have been mainly in polymerized form. Monomeric MIP-1 alpha rapidly decreased cycling rates and absolute numbers of myeloid progenitor cells in marrow and spleen. These effects, which occurred with about 1000-fold less MIP-1 alpha than we previously reported, were dose-dependent, time-related, and reversible. Suppressive effects were noted within 3 hours for cell cycling and within 24 hours for absolute numbers of progenitor cells in marrow and spleen and were lost by 48 hours. Decreased circulating neutrophils were noted at 48 hours. Column-separated polymerized rmMIP-1 alpha was inactive in vivo. These results demonstrate the potency of low doses of monomeric MIP-1 alpha in vivo. Since clinical administration of large amounts of an agent that is mainly in an inactive form may result in severe pharmacological side effects, the information presented here is of relevance for potential clinical trials using MIP-1 alpha as a myelosuppressive/myeloprotective agent.

PubMed Disclaimer

Cited by

Mad2 haploinsufficiency protects hematopoietic progenitor cells subjected to cell-cycle stress in vivo and to inhibition of redox function of Ape1/Ref-1 in vitro.
Rohrabaugh SL, Hangoc G, Kelley MR, Broxmeyer HE. Rohrabaugh SL, et al. Exp Hematol. 2011 Apr;39(4):415-23. doi: 10.1016/j.exphem.2010.12.012. Epub 2011 Jan 7. Exp Hematol. 2011. PMID: 21216274 Free PMC article.
Mad2 is required for optimal hematopoiesis: Mad2 associates with c-Kit in MO7e cells.
Ito S, Mantel CR, Han MK, Basu S, Fukuda S, Cooper S, Broxmeyer HE. Ito S, et al. Blood. 2007 Mar 1;109(5):1923-30. doi: 10.1182/blood-2006-06-030841. Epub 2006 Oct 12. Blood. 2007. PMID: 17038523 Free PMC article.
Down-regulation of the myeloid homeobox protein Hex is essential for normal T-cell development.
Mack DL, Leibowitz DS, Cooper S, Ramsey H, Broxmeyer HE, Hromas R. Mack DL, et al. Immunology. 2002 Dec;107(4):444-51. doi: 10.1046/j.1365-2567.2002.01523.x. Immunology. 2002. PMID: 12460189 Free PMC article.
Molecular machinations: chemokine signals in host-pathogen interactions.
Chensue SW. Chensue SW. Clin Microbiol Rev. 2001 Oct;14(4):821-35, table of contents. doi: 10.1128/CMR.14.4.821-835.2001. Clin Microbiol Rev. 2001. PMID: 11585787 Free PMC article. Review.
Regulation of hematopoiesis by chemokine family members.
Broxmeyer HE. Broxmeyer HE. Int J Hematol. 2001 Jul;74(1):9-17. doi: 10.1007/BF02982544. Int J Hematol. 2001. PMID: 11530812 Review.

Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 alpha - PubMed (original) (raw)